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ABSTRACT.
Purpose: To assess the eﬀect of an intravitreal ocriplasmin injection on visual
function, measured using visual acuity (VA) and vision-related quality of life.
Methods: Post hoc analysis of prespeciﬁed secondary end-points in two multi-
centre, randomized, double-masked, phase 3 clinical trials. A total of 652
participants with symptomatic vitreomacular adhesion were enrolled, of whom
464 received a single intravitreal injection of 125 lg ocriplasmin and 188 received
a single intravitreal placebo injection. Based on principal components analysis
results, visual function response (VFR) was deﬁned as either a VA improvement of
≥2 lines; or an improvement in the composite score of the National Eye Institute
Visual Function Questionnaire (VFQ-25) exceeding the minimal clinically
important diﬀerence (MCID), estimated using the standard error of measurement
approach; or an improvement in the VFQ-25 driving subscale score exceeding the
MCID. The main outcome measure was VFR at 6 months.
Results: A VFR occurred in 55.1% of the ocriplasmin group versus 34.2% of the
placebo injection group (p < 0.0001). This comprised 23.7% versus 11.2% (p =
0.0003) with a ≥ 2-line VA improvement, 35.9% versus 22.7% (p = 0.0016)
for the VFQ-25 composite score, and 10.2% versus 6.2% (p = 0.1697) for the
driving subscale.
Conclusion: Ocriplasmin produces a clinically meaningful visual function
beneﬁt.
Key words: macular hole – minimal clinically important diﬀerence – ocriplasmin – principal
components analysis – symptomatic vitreomacular adhesion/vitreomacular traction – VFQ-25
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Introduction
Symptomatic vitreomacular adhesion
(sVMA) describes visual dysfunction
caused or aggravated by vitreomacular
traction (VMT). It results from in-
complete posterior vitreous detachment
(PVD), where residual vitreous traction
leads to structural and functional dam-
age of the macula. It can occur as
isolated VMT, but it is also thought to
play a pivotal role in the development
of macular holes (Gaudric et al. 1999;
Chauhan et al. 2000; Tanner et al.
2001). It may also coexist with epireti-
nal membrane (ERM). More contro-
versially, sVMA may inﬂuence the
clinical course of diseases such as age-
related macular degeneration and dia-
betic macular oedema (Lee & Koh
2011; Maier et al. 2012; Simpson et al.
2012; Waldstein et al. 2012; Latalska
et al. 2013; Kang & Koh 2015).
Compared to many other retinal
conditions, limited epidemiological
data exist for sVMA, but it may aﬀect
as many as 15 people per 1000 (Jack-
son et al. 2013).
The current standard management of
VMT is either observation, with the
expectation that some cases may resolve
spontaneously, or pars plana vitrec-
tomy (PPV). Following the publication
of two phase 3 trials (ClinicalTrials.
gov identiﬁer: NCT00781859 and
NCT00798317), an intravitreal injec-
tion of ocriplasmin 125 lg has emerged
as an alternative treatment in patients
with sVMA/VMT, including when
associated with a macular hole (Stal-
mans et al. 2012). The primary outcome
of these trials was non-surgical resolu-
tion of VMAatday 28 following a single
intravitreal injection of ocriplasmin. A
prespeciﬁed combined analysis of both
trials met its primary end-point with
26.5% of the ocriplasmin-injected par-
ticipants responding, compared
with 10.1% of the placebo-injected par-
ticipants (p < 0.001). In addition, in
participants with a macular hole at
baseline, non-surgical closure of macu-
larholesatday28occurred in43 (40.6%)
of 106 ocriplasmin-treated participants,
compared with 5 (10.6%) of 47 placebo-
treated participants (p < 0.001).
The trial also reported several
predetermined secondary end-points,
including the percentage of participants
gaining at least three lines of best-
corrected visual acuity (BCVA) and
visual function measured using the
National Eye Institute Visual Function
Questionnaire (VFQ-25), both of which
signiﬁcantly favoured the ocriplasmin
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group (Stalmans et al. 2012). However,
it is not certain if a 3-line VA gain was
the best threshold, compared with the
more commonly used 2-line VA gain, as
many participants presented with rela-
tively good VA, making it diﬃcult to
gain three lines, and such a high
threshold may fail to detect clinically
relevant improvements in vision. For
example, the median VA at presenta-
tion was 67 letters (Snellen equivalent
20/55), so that half of the participants
would need to obtain at least 82 letters
(20/23) to gain 3 lines (15 letters) (Beck
et al. 2003; EMA 2013). Also, many
patients with VMT and macular hole
may have speciﬁc symptoms, such as
metamorphopsia, which are not well
detected by VA testing.
We hypothesized that there may be a
more sensitive and meaningful way of
measuring the visual function changes
that occur following treatment with
ocriplasmin. To test this hypothesis, we
aimed ﬁrst to deﬁne a clinically mean-
ingful threshold of visual function
response (VFR) and secondly to deter-
mine whether ocriplasmin produced a
beneﬁt using this threshold. We did this
using a post hoc analysis of the com-
bined data obtained during the two
phase 3 trials, looking speciﬁcally at
VA and the VFQ-25.
Materials and Methods
Participants
Studies TG-MV-006 and TG-MV-007
(hereafter referred to as 006 and 007)
have been described in detail (Stalmans
et al. 2012). In brief, both were multi-
centre, double-masked, placebo-con-
trolled phase 3 eﬃcacy and safety
studies, with a total of 652 participants
in the combined analysis. Adult partic-
ipants were eligible if they had sVMA
visible on optical coherence tomogra-
phy (OCT). All eyes had either VMT
alone or VMT associated with a macu-
lar hole. An ERMwas present in 38.7%
of eyes. Participants received a sin-
gle intravitreal injection of 125 lg
of ocriplasmin or placebo and were
reviewed over 6 months. Investigators
could refer participants for PPV at any
time if there was a clinical deterioration,
at his or her discretion. Institutional
Review Board (IRB)/Ethics Committee
approval was obtained at each partici-
pating site, and all participants provided
written informed consent. The studies
were conducted in accordance with the
Declaration of Helsinki.
Assessment of visual function
These post hoc analyses explored the
change in VA outcomes and VFQ-25
scores from baseline to month 6. Best-
corrected VA was measured using the
Early Treatment of Diabetic Retinopa-
thy Study (ETDRS) chart read at 4 m
(Early Treatment Diabetic Retinopathy
Study research group 1985). The VFQ-
25 (2000 version) was self-administered
in the participant’s native language
(Mangione et al. 2001). The VFQ-25
comprises 25 questions that require the
patient to assess the levels of diﬃculty of
particular visual symptoms or day-to-
day activities. Each question is assigned
to one of the following 12 subscales:
general health, general vision, ocular
pain, near activities, distance activities,
social functioning, mental health, role
diﬃculties, dependency, driving, colour
vision and peripheral vision. The sub-
scales scores range from 0 to 100, where
100 indicates the highest possible func-
tion or minimal subjective impairment.
The VFQ-25 composite score is calcu-
lated as the average of the vision-
targeted subscale scores, excluding the
question on general health (RAND
Corporation 2000). The questionnaire
has a few optional questions, none of
which were used in the trials.
Deﬁning visual function response
We aimed to deﬁne a visual function
response (VFR) such that participants
could be classiﬁed as responders or non-
responders. There was no reported def-
inition ofVFR for sVMA.The available
visual outcomes data set included VA
and VFQ-25 scores. The VFQ-25 Ques-
tionnaire results in a large number of
scores, which can make it diﬃcult to
interpret. Further, some questions may
be closely correlated with others, such
that one aspect of visual function has a
disproportionate eﬀect on the VFQ-25
composite score. Conversely, other
questions that assess another aspect of
visual function may fail to inﬂuence the
composite score. A principal compo-
nents analysis (PCA) is an accepted
means of validating new questionnaires,
but it is also a means of validating
established questionnaires when applied
to new disease states (Dougherty &
Bullimore 2010; Abetz et al. 2011).
The VFQ-25 has been validated in
several eye diseases, but not in sVMA.
We therefore performed a PCA to help
validate our use of the VFQ-25 and the
composite score as a summary measure.
A PCA works by grouping together
questions whose scores are closely
correlated into new variables called
principle components (PCs), on the
assumption that these are assessing
similar aspects of visual function (Jol-
liﬀe 2014). The PCs are ordered by the
amount of variation they capture such
that the ﬁrst few PCs are the most
relevant. In our data set, the ﬁrst PCwas
highly correlated with the composite
score, which makes it therefore a valid
summary measure of most of the infor-
mation contained in the VFQ-25. The
PCA further showed that the questions
related to driving, which were mostly
captured in the second PC, provided
independent information that is com-
plementary to the composite score.
Visual function response (VFR) was
therefore deﬁned as an improvement in
any one of the three measures: VA, the
VFQ-25 composite score and the VFQ-
25 driving subscale score, which corre-
sponded to the ﬁrst three dimensions of
visual functioning according to the
PCA. For each of these visual function
measures, we required a threshold that
deﬁned a VFR. Such thresholds should
reﬂect the minimal clinically important
diﬀerence (MCID). For VA, the MCID
was set at 10 letters, corresponding to
two lines, as this is a widely used
standard and was likely to be more
sensitive to change than the three-line
gainers used by Stalmans et al. (Early
Treatment Diabetic Retinopathy Study
research group 1985, Matza et al. 2008;
Stalmans et al. 2012). There was, how-
ever, no accepted or reported MCID
threshold for VFQ-25 scores of partic-
ipants with sVMA. In other ophthal-
mological conditions, the MCID is
based on a clinical anchor, usually VA,
or distribution metrics such as the stan-
dard error of measurement (SEM)
(Wyrwich et al. 1999; Cella et al. 2002;
Naik et al. 2013). Because the VA cor-
related relatively poorly with the VFQ-
25 composite score (Pearson’s correla-
tion coeﬃcient = 0.17 for the baseline
values and 0.26 for the change between
baseline and month 6 values), VA was
not used as clinical anchor, and the SEM
method was selected to determine the
MCID in a prespeciﬁed analysis plan.
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Any participants undergoing vitrec-
tomy were classiﬁed as non-responders.
Because ocriplasmin treatment has been
shown to prevent PPV in some partici-
pants with sVMA, this could potentially
favour the ocriplasmin group. A sensi-
tivity analysis was therefore conducted
to compare the response rates with-
out systematically classifying those
participants who had a PPV as non-
responders.
Statistical methods
Analyses were performed on the com-
bined data sets of both trials, including
all randomized participants, according
to the intent-to-treat principle. Missing
data for VA were imputed using the
last observation carried forward. The
VFQ-25 scores were computed on
observed values as per the VFQ-25
scoring algorithm.
The treatment eﬀect on the VFR
rates was estimated through logistic
regression incorporating study as a
ﬁxed eﬀect, and the likelihood ratio
test was used to test whether the odds
ratio diﬀered from 1 (an odds ratio of 1
corresponds to no diﬀerence between
the ocriplasmin and placebo group as
the same odds of response prevails in
both groups). All tests were considered
signiﬁcant if p < 0.05. All analyses
were carried out using SAS version 6.3
(SAS Inc., Cary, NC, USA).
Results
The ocriplasmin and placebo groups
were comparable in baseline demo-
graphics; 29 (6.3%) ocriplasmin-
treated and 16 (8.5%) placebo-treated
participants were discontinued from
the studies. A total of 82 (17.7%)
ocriplasmin-treated and 50 (26.6%)
placebo-treated participants required
a PPV by month 6 (p = 0.02).
Baseline VA was assessed in all but
one participant and in all participants
that reached month 6. The VFQ-25
Questionnaire completion rates at
baseline and at month 6 were high
(99.6% and 92.7% in the ocriplasmin
group and 99.5% and 92.6% in the
placebo group, respectively). The VFQ-
25 mean scores at baseline for each
question were comparable between the
two treatment groups, but varied con-
siderably between the diﬀerent VFQ-25
items; in the ocriplasmin group for
example, the mean score for the
question, ‘How much do you worry
about your eyesight’ was 51.7 com-
pared with a mean score of 92.4 for
‘visiting with people’ (Table 1).
The ﬁrst principal component from
the PCA using all functional vision
questions of the VFQ-25 responses
captured 41.1% of the total variability
or information in the visual outcomes
data set and was highly correlated with
the VFQ-25 composite score (Pearson’s
correlation coeﬃcient of 0.98). The
second principal component captured
an additional 7.1% of the total vari-
ability, but had a high loading (0.58)
for one of the VFQ-25 driving items
(question 16). The VFQ-25 composite
score and the driving subscale score
were therefore kept as valid summary
measures of patient-reported visual
function determined by the VFQ-25
scores. The MCID threshold for deﬁn-
ing a responder, based on the SEM
method, was 3.6 points for the VFQ-25
composite score and 19.1 points for the
VFQ-25 driving subscale score.
Ocriplasmin treatment resulted in
a signiﬁcantly higher proportion of
responders for VA deﬁned as an
improvement of ≥ 2 lines (23.7% ver-
sus 11.2% in the placebo group, OR:
2.51, p = 0.0003) and for the VFQ-25
composite score deﬁned as an improve-
ment of ≥3.6 points (35.9% versus
22.7% in the placebo group, OR:
1.92, p = 0.0016) (Table 2). Ocriplas-
min treatment also increased the pro-
portion of participants with an
improved driving score, deﬁned as an
improvement of ≥19.1 points, but this
increase was not statistically signiﬁcant
(10.2% versus 6.2% in the placebo
group, OR: 1.71, p = 0.1697). A total
of 55.1% of participants treated with
ocriplasmin improved on any of these
three visual function scores, versus
34.2% of placebo participants (OR:
2.28, p < 0.0001) (Table 2).
The sensitivity analyses, in which
participants who underwent PPV
between baseline and 6 months after
the injection were not automatically
classiﬁed as visual function non-respon-
ders, gave similar results as the primary
analysis (Table 2).
Discussion
Based on the PCA results, three scores
were used as measures of visual func-
tioning, as each of them represents
another dimension of visual
functioning: the VA score, and the
overall composite score and driving
subscale score of the VFQ-25. Ocriplas-
min treatment resulted in a better
response for all three measures,
although the diﬀerence did not reach
signiﬁcance for the driving subscale. The
proportion of ocriplasmin-treated par-
ticipants who responded to at least one
of these visual function measures was
55.1%, signiﬁcantly higher than the
34.2% seen in the placebo-injected par-
ticipants.
We are not aware of any published
reports using visual function question-
naires to assess the eﬀect of PPV in
patients with VMT. Three studies used
the VFQ-25 to assess the eﬀect of PPV
for treating idiopathic macular hole. At
one year postoperatively, the VFQ-25
composite score improved by 5.6 points
in one study and by 12.2 points in
another study (Hirneiss et al. 2007;
Duan et al. 2015). A further study
reported a VFQ-25 composite score
improvement by 6.2 points at 4 months
postoperatively (Tranos et al. 2004).
The anatomical success rates were
96.6%, 97.2% and 86.6%, respectively.
All three studies included a range of
macular hole stages with results aggre-
gated for stage II to IV macular holes.
In the combined phase 3 ocriplasmin
studies, participants treated with
ocriplasmin showed an overall im-
provement of 3.4 points in the VFQ-
25 composite score at 6 months. When
considering ocriplasmin-treated partic-
ipants with a macular hole at baseline
who achieved non-surgical macular
hole closure at month 6, the VFQ-25
composite score improved by 9.0 points
(N = 40, observed cases analysis).
Within the limitations of such an indi-
rect comparison across studies, this
suggests that ocriplasmin, as a phar-
macological alternative to PPV, may
result in a similar improvement of
visual functioning.
In the absence of a good correlation
between VA and the VFQ-25, the SEM
was used as a distribution-based mea-
sure to estimate the MCID for the
VFQ-25 composite score and the driv-
ing subscale. The SEM for the
composite score was 3.6. Published
evidence on MCID thresholds for the
VFQ-25 composite score is very lim-
ited, with none reported for either
macular hole or VMT. The Submacu-
lar Surgery Trials Research Group
suggested that a 4-point change in the
3
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composite score would correspond to a
minimal clinically meaningful change,
based on the combined data of three
trials (Submacular Surgery Trials
Research Group 2007). Su~ner and col-
leagues found a 4- to 6-point change in
the VFQ-25 scores to correspond to a
clinically meaningful change, using a
15-letter change in the VA as an anchor
among participants with neovascu-
lar age-related macular degeneration
(Su~ner et al. 2009). Our SEM for the
driving subscale score is quite large
(19.1) and as far as we know has not
been determined previously.
The relatively low correlation
between the VA and VFQ-25 scores
has been seen in studies for other oph-
thalmology disorders (Hirneiss et al.
2007; Orr et al. 2011; Varma et al.
2012). The absence of such correlation
suggests that the improvement in the
patient-reported visual functioning, as
measured by the VFQ-25 scores, is
largely independent of the change in
VA, conﬁrming the relevance of our
hypothesis and research.
This apparent absence of correlation
between VA and VFQ-25 responses
may be due to unmeasured symptoms
such as metamorphopsia, which is
known to aﬀect visual functioning.
Metamorphopsia may impact on a
patient’s subjective visual experience
without a commensurate change in
VA, and hence, a VFR may be a more
sensitive means of detecting visual
dysfunction than VA testing. In a study
of the eﬀect of PPV for ERM, Oka-
moto and colleagues found a signiﬁ-
cant (negative) correlation between
the VFQ-25 composite score and the
severity of metamorphopsia, but no
correlation with VA outcomes, both
pre- and postoperative (Okamoto et al.
2009). They further showed that a
change in the severity of metamor-
phopsia was the single explanatory
factor relevant to a change in the
VFQ-25 composite score in partici-
pants with macular hole and ERM,
suggesting the VFQ-25 may in part
reﬂect symptoms such as metamor-
phopsia (Okamoto et al. 2010).
The driving subscale score correlates
poorly with the composite score. Sim-
ilar observations have been made in
other studies (Massof & Fletcher 2001;
Dougherty & Bullimore 2010; Marella
et al. 2010). The absence of a signiﬁ-
cant diﬀerence across treatment groups
in the driving subscale scores may be
related to the relatively small number
of participants included in this analysis.
Many of the participants in the 006 and
007 trials have never driven or gave up
driving for reasons other than their
eyesight, and hence, their data are
considered missing.
This analysis has several strengths.
The randomized, double-masked design
suggests the observed diﬀerencesmay be
causal and unbiased, the visual and
functional outcomes were collected rig-
orously within a clinical trial, and the
total sample size was suﬃciently large to
detectmeaningful clinical diﬀerences for
mostmeasures. Compared to two recent
ocriplasmin publications, this analysis
applied a scientiﬁcally acceptedmethod,
PCA, to condense the available visual
function information into one dimen-
sion (outcomemeasure), which captures
the full treatment eﬀect (Gandorfer
et al. 2015; Varma et al. 2015). Also,
this study compared results in the
ocriplasmin group to the original con-
trol group.Unlike other studies, we used
a data-driven technique to establish the
MCID for the VFQ-25 composite and
driving subscale scores in subjects with
VMT (Gandorfer et al. 2015; Varma
et al. 2015).
Limitations of this study include the
fact that the baseline score for many
questions was quite high, resulting in a
high mean VFQ-25 composite baseline
score, leaving limited room for improve-
ment. Also, the placebo injection may
have caused some improvement in the
visual function in the control group, as
the clinical trial data suggest and as
recently observed in the sham injection
group of the OASIS trial (ClinicalTri-
als.gov identiﬁer: NCT01429441)
(Dugel PU et al. 2016, Stalmans et al.
2012). This would also reduce the per-
ceived beneﬁt in the ocriplasmin group
and may not translate to the usual
clinical environment, where ocriplasmin
is an alternative to observation or PPV.
In conclusion, treatment with ocri-
plasmin resulted in a large and clini-
cally meaningful visual function beneﬁt
in addition to its anatomical eﬀect on
sVMA resolution. Participants treated
with ocriplasmin beneﬁtted from an
additional visual function improve-
ment of 20% compared with placebo,
when considering a clinically meaning-
ful improvement in at least one of three
visual function measures. These bene-
ﬁts included a greater proportion of
patients with a 2-line VA gain, but
importantly there were other functional
visual improvements, suggesting that
VA alone may not fully capture the
beneﬁts of treatment.
Table 2. Visual function response by treatment group in the combined studies TG-MV-006 and TG-MV-007.
Measure
Primary analysis Sensitivity analysis*
Ocriplasmin Placebo
OR (95% CIs)
Ocriplasmin Placebo
OR (95% CIs)n/N % n/N % n/N % n/N %
VA 110/464 23.7 21/188 11.2 2.51 (1.52,4.16)‡ 130/464 28.0 32/187 17.1 1.91 (1.24, 2.95)‡
VFQ-25 composite score 158/440 35.9 40/176 22.7 1.92 (1.28, 2.88)‡ 186/428 43.5 57/173 33.0 1.58 (1.09, 2.29)†
Driving subscale 35/344 10.2 9/146 6.2 1.71 (0.80, 3.65) 41/319 12.9 12/140 8.6 1.54 (0.78, 3.04)
Overall VFR 217/394 55.1 53/155 34.2 2.28 (1.54, 3.37)‡ 256/377 67.9 76/148 51.4 1.90 (1.28, 2.81)‡
VA = responder with respect to visual acuity diﬀerence from baseline to month 6 (increase ≥2 lines); VFQ-25 composite score = responder with
respect to VFQ-25 composite score diﬀerence from baseline to month 6 (increase ≥ 3.6); driving subscale = responder with respect to driving subscale
score diﬀerence from baseline to month 6 (increase ≥ 19.1); overall VFR: a positive response to the VFQ-25 composite score or VA or driving
subscale score; OR = odds ratio (ocriplasmin compared to placebo); CIs = conﬁdence intervals.
*In the sensitivity analysis, participants who had a PPV between baseline and month 6 are not automatically classiﬁed as visual function non-
responders.
†p value < 0.05.
‡p value < 0.01.
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